Q2 EPS Estimate for Sana Biotechnology Increased by Analyst

Sana Biotechnology, Inc. (NASDAQ:SANA) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Sana Biotechnology in a research report issued on Tuesday, April 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology’s FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.65) EPS.

Several other equities analysts also recently commented on SANA. Zacks Research downgraded shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Bank of America boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wedbush upped their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday. Morgan Stanley reissued an “overweight” rating and set a $12.00 price objective on shares of Sana Biotechnology in a report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.20.

Sana Biotechnology Trading Up 0.9%

Sana Biotechnology stock opened at $3.47 on Thursday. Sana Biotechnology has a 1-year low of $1.58 and a 1-year high of $6.55. The firm’s fifty day simple moving average is $3.48 and its 200-day simple moving average is $4.12. The company has a market capitalization of $926.04 million, a P/E ratio of -3.58 and a beta of 2.06.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03).

Institutional Trading of Sana Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SANA. Mercer Global Advisors Inc. ADV acquired a new position in shares of Sana Biotechnology during the third quarter worth approximately $36,000. Lyell Wealth Management LP acquired a new stake in shares of Sana Biotechnology in the third quarter worth $37,000. TD Waterhouse Canada Inc. bought a new position in Sana Biotechnology during the third quarter worth $37,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Sana Biotechnology during the third quarter worth $39,000. Finally, Rockefeller Capital Management L.P. raised its stake in Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.